Pro Medicus Limited (ASX:PME) Signs A$170M, 10-Year Contract with UCHealth
Pro Medicus Limited (ASX:PME) signs a A$170M, 10-year contract with UCHealth to implement its Visage 7 imaging platform.
Category: Companies
Invictus Energy Ltd (ASX:IVZ) Updates on PPSA and National Project Status
Invictus Energy Ltd (ASX:IVZ) announces progress on PPSA and National Project Status for Cabora Bassa Project in Zimbabwe.
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) Completes StemSmart Acquisition
NeuroScientific Biopharmaceuticals Ltd (ASX:NSB) completes acquisition of StemSmart technology, appoints new directors, and launches clinical program for Crohn’s disease treatment.
Celsius Resources Limited (ASX:CLA) Commences Engineering Activities for MCB Project
Celsius Resources (ASX:CLA) begins engineering for its MCB Copper-Gold Project and extends SODOR’s share return period.
Sunrise Energy Metals Limited (ASX:SRL) Reports High-Grade Scandium Assays at Syerston
Sunrise Energy Metals (ASX:SRL) announces significant high-grade scandium assay results from its Syerston drilling campaign.
PYC Therapeutics (ASX:PYC) Advances PMS Drug Candidate to Clinical Trials
PYC Therapeutics (ASX:PYC) advances its PMS drug candidate, PYC-002, with promising data supporting its progression to clinical trials.
North Stawell Minerals (ASX:NSM) Announces $3.6M Capital Raising
North Stawell Minerals (ASX:NSM) announces a $3.6M capital raise to fund exploration initiatives at Darlington and Wildwood projects.
Duxton Farms Ltd (ASX:DBF) Announces Strategic Merger and Special Dividend
Duxton Farms (ASX:DBF) announces a strategic merger to expand its agricultural portfolio and declares an 85% special dividend.
Percheron Therapeutics (ASX:PER) Secures Worldwide License for HMBD-002
Percheron Therapeutics (ASX:PER) secures exclusive worldwide license for HMBD-002, advancing its oncology drug pipeline and future clinical trials.
Aurizon Holdings Limited (ASX:AZJ) Announces FY2025 EBITDA and Leadership Restructuring
Aurizon Holdings Limited (ASX:AZJ) anticipates FY2025 EBITDA of $1.575b and announces a leadership restructuring to enhance operational synergy.